AU770165B2 - Process for formulation of carbapenem antibiotic compositions - Google Patents

Process for formulation of carbapenem antibiotic compositions Download PDF

Info

Publication number
AU770165B2
AU770165B2 AU12456/01A AU1245601A AU770165B2 AU 770165 B2 AU770165 B2 AU 770165B2 AU 12456/01 A AU12456/01 A AU 12456/01A AU 1245601 A AU1245601 A AU 1245601A AU 770165 B2 AU770165 B2 AU 770165B2
Authority
AU
Australia
Prior art keywords
carbapenem
temperature
solution
formulation
vials
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU12456/01A
Other languages
English (en)
Other versions
AU1245601A (en
Inventor
Anthony Al-Dehneh
William A. Hunke
Kathleen J. Illig
Anand Kanike
Hiren Patel
Scott D. Reynolds
Stelios C. Tsinontides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1245601A publication Critical patent/AU1245601A/en
Application granted granted Critical
Publication of AU770165B2 publication Critical patent/AU770165B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU12456/01A 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions Expired AU770165B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16248299P 1999-10-29 1999-10-29
US60/162482 1999-10-29
PCT/US2000/029869 WO2001032172A1 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions

Publications (2)

Publication Number Publication Date
AU1245601A AU1245601A (en) 2001-05-14
AU770165B2 true AU770165B2 (en) 2004-02-12

Family

ID=22585803

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12456/01A Expired AU770165B2 (en) 1999-10-29 2000-10-27 Process for formulation of carbapenem antibiotic compositions

Country Status (8)

Country Link
EP (1) EP1244444B1 (enExample)
JP (1) JP4854899B2 (enExample)
AT (1) ATE285770T1 (enExample)
AU (1) AU770165B2 (enExample)
CA (1) CA2388163C (enExample)
DE (1) DE60017194T2 (enExample)
ES (1) ES2234689T3 (enExample)
WO (1) WO2001032172A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548492B1 (en) * 1999-10-29 2003-04-15 Merck & Co., Inc. Process for formulation of carbapenem antibiotic compositions
JP2005522422A (ja) * 2002-02-01 2005-07-28 シモダ、バイオテック（プロプライエタリー）リミテッド 医薬組成物
EP2505191A1 (en) * 2008-06-11 2012-10-03 Ranbaxy Laboratories Limited Lyophilized Carbapenem antibiotic composition
US8691803B2 (en) 2011-01-24 2014-04-08 Savior Lifetec Corporation Process for the preparation of antibiotic compounds
US10016383B2 (en) 2013-05-07 2018-07-10 Mcmaster University Inhibitors of metallo-β-lactamase-enzymes
KR101587420B1 (ko) * 2014-08-20 2016-01-22 주식회사 대웅제약 에르타페넴-함유 동결건조제제의 제조방법
KR20170014842A (ko) 2015-07-31 2017-02-08 주식회사 대웅제약 개선된 에르타페넴 주사제의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018800A1 (en) * 1996-10-28 1998-05-07 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
US5952323A (en) * 1996-05-28 1999-09-14 Merck & Co., Inc. Carbapenem antibiotic
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970281B1 (en) * 1996-05-28 2002-04-30 Merck & Co Inc Carbapenem antibiotic, composition and method of preparation
JP3245427B2 (ja) * 1997-06-16 2002-01-15 メルク エンド カンパニー インコーポレーテッド 安定化されたカルバペネム中間体および合成における使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952323A (en) * 1996-05-28 1999-09-14 Merck & Co., Inc. Carbapenem antibiotic
WO1998018800A1 (en) * 1996-10-28 1998-05-07 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making

Also Published As

Publication number Publication date
ATE285770T1 (de) 2005-01-15
WO2001032172A1 (en) 2001-05-10
CA2388163A1 (en) 2001-05-10
JP2003514779A (ja) 2003-04-22
EP1244444B1 (en) 2004-12-29
CA2388163C (en) 2009-08-25
AU1245601A (en) 2001-05-14
DE60017194T2 (de) 2005-12-22
DE60017194D1 (de) 2005-02-03
EP1244444A1 (en) 2002-10-02
JP4854899B2 (ja) 2012-01-18
ES2234689T3 (es) 2005-07-01
EP1244444A4 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
US6548492B1 (en) Process for formulation of carbapenem antibiotic compositions
EP2504353B1 (en) Lipopeptide compositions and related methods
SA04250119B1 (ar) تركيبات تحتوي على بيبراسيللين piperacillin وتازوباكتام tazobactam تفيد في الحقن
US7468428B2 (en) Lyophilized azithromycin formulation
AU2001261079A1 (en) Process for formulation of antibiotic compounds
US20060116336A1 (en) Lyophilized azithromycin formulation
CA1056729A (en) Injectable amoxycillin composition
AU770165B2 (en) Process for formulation of carbapenem antibiotic compositions
MX2007004490A (es) Composiciones que contienen piperacilina, tazobactam y un acido aminocarboxilico en un diluyente de lactato de sodio.
CA3011436A1 (en) Formulations of vancomycin
US6486150B2 (en) Process for formulation of antibiotic compounds
CN103860485A (zh) 一种厄他培南钠冻干制剂及其制备方法
EP0278243B1 (en) Medical preparation comprising aspoxicillin, a method for its preparation, and the use of such a preparation for the manufacture of a medicament
WO2006115494A1 (en) Lyophilized azithromycin formulation
WO2012066492A1 (en) Processes for the preparation of carbapenem antibiotic composition
EP0381915B1 (en) Process for preparing alkali metal salts of 3,7-substituted 7-aminocephalosporanic acid derivatives.
HK1176367B (en) Lipopeptide compositions and related methods
HK1176367A (en) Lipopeptide compositions and related methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired